JP2021525765A5 - - Google Patents
Info
- Publication number
- JP2021525765A5 JP2021525765A5 JP2020566958A JP2020566958A JP2021525765A5 JP 2021525765 A5 JP2021525765 A5 JP 2021525765A5 JP 2020566958 A JP2020566958 A JP 2020566958A JP 2020566958 A JP2020566958 A JP 2020566958A JP 2021525765 A5 JP2021525765 A5 JP 2021525765A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- neoantigen
- pharmaceutically acceptable
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679699P | 2018-06-01 | 2018-06-01 | |
| US201862679696P | 2018-06-01 | 2018-06-01 | |
| US62/679,699 | 2018-06-01 | ||
| US62/679,696 | 2018-06-01 | ||
| PCT/US2019/034992 WO2019232433A2 (en) | 2018-06-01 | 2019-05-31 | Methods of using splicing modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525765A JP2021525765A (ja) | 2021-09-27 |
| JP2021525765A5 true JP2021525765A5 (https=) | 2022-06-06 |
| JP7346466B2 JP7346466B2 (ja) | 2023-09-19 |
Family
ID=67070907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566958A Active JP7346466B2 (ja) | 2018-06-01 | 2019-05-31 | スプライシング調節薬の使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11998544B2 (https=) |
| EP (1) | EP3801523B1 (https=) |
| JP (1) | JP7346466B2 (https=) |
| KR (1) | KR20210016406A (https=) |
| CN (1) | CN112367996B (https=) |
| AU (1) | AU2019279012A1 (https=) |
| BR (1) | BR112020024551A2 (https=) |
| CA (1) | CA3101205A1 (https=) |
| IL (2) | IL305047A (https=) |
| MX (1) | MX2020012940A (https=) |
| WO (1) | WO2019232433A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009906TA (en) * | 2018-04-09 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide compounds and their use |
| EP3801523B1 (en) | 2018-06-01 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Splicing modulators |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| SG11202102419VA (en) | 2018-12-13 | 2021-04-29 | Eisai R&D Man Co Ltd | Herboxidiene splicing modulator antibody-drug conjugates and methods of use |
| WO2021231908A2 (en) * | 2020-05-15 | 2021-11-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhancing cancer immunotherapy |
| AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU705688B2 (en) | 1995-11-10 | 1999-05-27 | Cytogen Corporation | Peptides which enhance transport across tissues and methods of identifying and using the same |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| CA2494536C (en) | 2002-07-31 | 2011-10-04 | Mercian Corporation | A 12-membered ring macrolide active substance |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| BR0316746A (pt) | 2002-11-29 | 2005-10-18 | Mercian Corp | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
| CN1886505A (zh) | 2003-11-27 | 2006-12-27 | 美露香株式会社 | 参与大环内酯类化合物的羟化作用的dna |
| US8008049B2 (en) | 2004-07-20 | 2011-08-30 | Eisai R&D Management Co., Ltd. | DNA coding for polypeptide participating in biosynthesis of pladienolide |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドｂ及びプラジエノライドｄの全合成方法 |
| EP2053393A1 (en) * | 2006-08-02 | 2009-04-29 | Eisai R&D Management Co., Ltd. | Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| LT3143016T (lt) * | 2014-05-15 | 2019-06-10 | Eisai R&D Management Co., Ltd. | Pladienolido piridino junginiai ir panaudojimo būdai |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| JP6876680B2 (ja) * | 2015-09-01 | 2021-05-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| RU2619208C2 (ru) | 2015-10-08 | 2017-05-12 | ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс | Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак |
| BR112018009995B1 (pt) | 2015-11-18 | 2024-04-30 | Eisai R&D Management Co., Ltd | Forma cristalina, composição farmacêutica, e, uso da forma cristalina |
| PE20231050A1 (es) | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| WO2017214182A1 (en) * | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| US10825015B2 (en) | 2018-03-07 | 2020-11-03 | Capital One Services, Llc | Secure payment using a network of wearable devices |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| EP3801523B1 (en) | 2018-06-01 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Splicing modulators |
| SG11202102419VA (en) | 2018-12-13 | 2021-04-29 | Eisai R&D Man Co Ltd | Herboxidiene splicing modulator antibody-drug conjugates and methods of use |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| JP7821733B2 (ja) | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
-
2019
- 2019-05-31 EP EP19733906.2A patent/EP3801523B1/en active Active
- 2019-05-31 KR KR1020207037344A patent/KR20210016406A/ko not_active Ceased
- 2019-05-31 CA CA3101205A patent/CA3101205A1/en active Pending
- 2019-05-31 WO PCT/US2019/034992 patent/WO2019232433A2/en not_active Ceased
- 2019-05-31 IL IL305047A patent/IL305047A/en unknown
- 2019-05-31 BR BR112020024551-8A patent/BR112020024551A2/pt unknown
- 2019-05-31 MX MX2020012940A patent/MX2020012940A/es unknown
- 2019-05-31 IL IL278740A patent/IL278740B2/en unknown
- 2019-05-31 US US17/059,876 patent/US11998544B2/en active Active
- 2019-05-31 AU AU2019279012A patent/AU2019279012A1/en not_active Abandoned
- 2019-05-31 JP JP2020566958A patent/JP7346466B2/ja active Active
- 2019-05-31 CN CN201980042241.3A patent/CN112367996B/zh active Active
-
2024
- 2024-04-25 US US18/645,759 patent/US20240350484A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525765A5 (https=) | ||
| Sathyanarayanan et al. | Cancer immunotherapy: Strategies for personalization and combinatorial approaches | |
| Tai et al. | Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells | |
| Amann et al. | Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3 | |
| JP2020506971A5 (https=) | ||
| Jurianz et al. | Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2 | |
| JP2021512914A5 (https=) | ||
| JP2018509175A (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| JP2020521478A5 (https=) | ||
| WO2020257760A1 (en) | Anti-tigit antibodies | |
| Rothschild et al. | Immunotherapy in head and neck cancer-scientific rationale, current treatment options and future directions | |
| RU2015140122A (ru) | Новые конъюгаты антител и их применения | |
| HRP20220133T1 (hr) | Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe | |
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| JP2022512401A5 (https=) | ||
| US20230279105A1 (en) | Anti-tim-3 antibodies | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| JP2023503901A (ja) | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム | |
| JP2022512672A5 (https=) | ||
| JP2024531944A5 (https=) | ||
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| JP2023523083A5 (https=) | ||
| JP2022547274A5 (https=) | ||
| CN113454114A (zh) | 治疗癌症的药物组合 | |
| JPWO2023008462A5 (https=) |